Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEDICAL THERAPY FOR ISCHEMIC STROKE
Autore:
SILVER B; WEBER J; FISHER M;
Indirizzi:
MED CTR CENT MASSACHUSETTS,DEPT NEUROL,119 BELMONT ST WORCESTER MA 01605 MED CTR CENT MASSACHUSETTS,DEPT NEUROL WORCESTER MA 01605 UNIV MASSACHUSETTS,MED CTR WORCESTER MA 00000
Titolo Testata:
Clinical neuropharmacology
fascicolo: 2, volume: 19, anno: 1996,
pagine: 101 - 128
SICI:
0362-5664(1996)19:2<101:MTFIS>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
TISSUE-PLASMINOGEN-ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; ACUTE MYOCARDIAL-INFARCTION; TRANSIENT FOREBRAIN ISCHEMIA; CENTRAL NERVOUS-SYSTEM; INTRAARTERIAL FIBRINOLYTIC THERAPY; GLUTAMATE ANTAGONIST MK-801; CORONARY-ARTERY REPERFUSION; LEFT-VENTRICULAR FUNCTION;
Keywords:
THROMBOLYSIS; STROKE; CYTOPROTECTIVE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
273
Recensione:
Indirizzi per estratti:
Citazione:
B. Silver et al., "MEDICAL THERAPY FOR ISCHEMIC STROKE", Clinical neuropharmacology, 19(2), 1996, pp. 101-128

Abstract

Therapy for stroke is undergoing major changes. Many of the changes parallel the advances made in the therapy for myocardial infarction. Acute intervention with cytoprotective and thrombolytic agents is undergoing active investigation. Cytoprotective therapy includes drugs that act to prevent cell death during ischemia and reperfusion. These agents include calpain inhibitors, voltage-sensitive calcium- and sodium-channel antagonists, receptor-mediated calcium-channel antagonists [including N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) antagonists], glutamate-synthesis inhibitors, glutamate-release antagonists, gamma-aminobenzoic acid (GABA)antagonists, 5-HT (serotonin) receptor agonists, gangliosides, antioxidants, growth factors, antiapoptotic agents, and antiadhesion molecules. Thrombolysis is effective in myocardial infarction. Thrombolysis is undergoing evaluation in stroke with streptokinase, anisoylated plasminogen streptokinase activator complex (APSAC), tissue plasminogen activator (t-PA; including recombinant t-PA), urokinase, and single-chain urokinase (scu-PA). Both systemic and selective administration are being evaluated. Preventive therapy with both antiplatelet and anticoagulant drugs sheds new light on how best to stratify patients in terms of a risk-benefit ratio. Continuing public education will be essentialas stroke therapy advances.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 19:29:46